300142 Walvax Biotechnology
- 13.54
- -0.80-5.58%
Walvax Biotechnology News
Watson Biotech (300142) 2023 Three Quarter Report Commentary: PCV13 Indonesia Approved for Listing Q3 Results Under Short-Term Pressure
Watson Biology (300142) 2023 Interim Report Review: HPV Vaccine Competition Exceeds Expectations and Internationalization Accelerates
Watson Biotech (300142): 13-valent pneumonia and bivalent HPV dual-wheel drive performance continues to grow rapidly
Watson Biotech (300142): Rapid growth in research and development of two major vaccines is progressing steadily
Watson Biotech (300142) Review Report: Innovative Products Benefit, Overseas Markets Reach Higher Level
Watson Biotech (300142): First-time exporter of 13-valent pneumonia saw a high increase in revenue
Watson Biotech (300142): The 13-valent pneumonia and HPV vaccine dosage innovative product echelon is growing
Watson Biotech (300142): The release of major products accelerates the construction of a new platform for COVID-19 vaccine technology
Deepin*Company*Watson Biotech (300142): PCV13 continues to grow, and the HPV2+ mRNA vaccine is worth looking forward to
Watson Biotech (300142): 13-valent pneumonia is growing steadily, COVID-19 vaccine layout is complete
Watson Biotech (300142): Cash flow situation has improved dramatically, R&D projects and industrialization are progressing steadily
Watson Biotech (300142): OMICRON's continuous fermentation curve overtaking opportunities are highlighted
Watson Biology (300142) 2021 mid-report comments: 13 price sales volume in line with expectations waiting for phase III clinical results of MRNA COVID-19 vaccine
Deepin* Company* Watson Biotech (300142): Deepening the field of mRNA vaccines in all directions can be expected in the future
Watson Biotech (300142): PCV13 continues to release volume and comprehensively lays out the MRNA technology platform
Watson Biology (300142): Q2 single-quarter sales steadily resume 13-price pneumonia volume is expected
Deepin* Company* Watson Biotech (300142): Deeply involved in the vaccine industry and is committed to building the first domestically produced MRNA vaccine in China
Watson Biology (300142) Quarterly report 2021 Preview comments: strong growth in issuance of 13-valent pneumonia conjugate vaccine batches without affecting current performance through profit or loss
Watson Biotech (300142) 2020 Report Review: Performance Meets Expectations Rapid Release of the 13-Valent Pneumonia Vaccine
Deepin*Company*Watson Biotech (300142): PCV13's Successful Release Incentive Plan Shows Confidence
No Data
